CLINICAL TRIAL SUMMARY

MDACC Study No:DM03-0279 (clinicaltrials.gov NCT No: NCT00506129)
Title:Study of Allogeneic Transplantation in Patients with Cutaneous T-cell Lymphoma (CTCL)
Principal Investigator:Chitra M. Hosing
Treatment Agent:Fludarabine; Melphalan
Study Status:Closed
Study Description:The goal of this clinical research study is to see if receiving a transplant of
blood stem cells (cells that can produce blood) or bone marrow from either a
related donor (brother, sister or other relative) or an unrelated voluntary
donor will help patients with advanced cutaneous T-cell lymphoma. The length
of time that patients who receive the treatment remain free of disease will
also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Fludarabine
Melphalan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:The length of stay is approximately 30 days in hospital.
Supported By:N/A
Return Visit:As per bone marrow transplant routine. Patients remain in Houston, TX for 100
days after transplantation.
Home Care:As per bone marrow transplant routine.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Chitra M. Hosing
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults